Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Calculus Bovis Sativus for Ischemic Cerebrovascular Disease
NCT06474507Recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of calculus bovis sativus in ischemic cerebrovascular disease (3 arms), sponsored by Tongji Hospital. Primary endpoints: Modified Rankin Scale at 12 weeks, National Institutes of Health Stroke Scale at 12 weeks and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
calculus bovis sativus
03
Conditions
ischemic cerebrovascular disease
Beyond the preview
Go deeper on NCT06474507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474507.